Результаты поиска

Synergies of dibutyl phthalate on high-fat diet can aggravate cardiac fibrosis/dysfunction and the protective effects of vitamin E and salidroside: A molecular toxicological study in Sprague-Dawley rats.

BACKGROUND: Dibutyl phthalate (DBP) is a pollutant associated with plastic contamination and is commonly used as a plasticizer. It is linked to various adverse health effects, including cardiovascular disease (CVD). There is an association between DBP and high-fat diet (HFD), with HFD also contributing to the development of CVD, including cardiac fibrosis. Cardiac fibrosis is characterized by chronic inflammation of myocardial tissue and is a significant contributor to CVD pathogenesis. Recent research provides evidence suggesting a potential link between environmental exposure to DBP and card

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.

BACKGROUND: Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. METHODS: This study included all adult patients who received BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) or combinations BRAF/MEK inhibitors (vemurafenib/cobimetinib; dabrafenib/trametinib; encorafenib/binimetinib). We utilized the cross-sectional FDA's Adverse Events Reporting System (FAERS) and longitudinal Truven Health Analytics/IBM MarketScan database from 2011 to 2018. Various CVAEs, including arterial hypertension, heart fai

Toxicology and carcinogenesis studies of bis(2-chloroethoxy)methane (CAS No. 111-91-1) in F344/N rats and B6C3F1 mice (dermal studies).

UNLABELLED: Bis(2-chloroethoxy)methane is used as a solvent and the starting agent in the production of fungicides and polysulfide polymers. … sidered to be due, at least in part and probably exclusively, to bis(2-chloroethoxy)methane-induced cardiotoxicity. The incidence of ulceration of the forestomach was significantly increased in 600 mg/kg males. Significantly increased incidences of dermal inflammation and fibrosis and epidermal hyperplasia at the site of application occurred in 600 mg/kg male mi …

Pimozide for schizophrenia or related psychoses.

BACKGROUND: Pimozide, formulated in the 1960s, continues to be marketed for the care of people with schizophrenia or related psychoses such as delusional disorder. It has been associated with cardiotoxicity and sudden unexplained death. Electrocardiogram monitoring is now required before and during use. OBJECTIVES: To review the effects of pimozide for people with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.A secondary objective was to examine the effects of pimozide for people with delusional disorder. SEARCH METHODS: We sear…

Cardiac substructure dosimetry in postoperative breast-conserving radiotherapy: a novel 8-field IMRT approach for internal mammary node irradiation using MONACO.

OBJECTIVE: To evaluate the dosimetric impact of internal mammary lymph node (IMN) inclusion versus exclusion (non-IMN) on cardiac substructu … sion-making should carefully weigh the competing risks of locoregional recurrence against potential cardiotoxicity, with consideration given to advanced radiotherapy techniques for cardiac dose optimization when treating left-sided malignancies. 2. Current evaluation metrics for breast cancer radiotherapy planning, predominantly focused on mean heart dose and lo …

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin and/or oxaliplatin, is used to treat a variety of paediatric malignanci … CI 1.99 to 41.12; P = 0.004). No significant difference was identified between treatment groups for cardiotoxicity and renal toxicity grade 3 or 4. None of the studies evaluated quality of life. No eligible studies were found for possible otoprotective medical interventions other than amifostine and other types of malignancies. AUTHORS' CONCLUSIONS: At the mome …

[Sex, erectile dysfunction, and the heart: a growing problem].

BACKGROUND: Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance. ED may also be an early sign of cardiovascular disease. The main risk factors for coronary heart disease (high LDL, smoking, hypertension, diabetes) and ED are the same. ED after the diagnosis of coronary artery disease or myocardial infarction is also common. CARDIOVASCULAR EFFECTS AND RISK OF SEXUAL ACTIVITY: Cardiac and metabolic expenditures during sexual intercourse will vary depending on the type of sexual activity. When oxygen uptak

Incidental COVID-19 in a heart-kidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS-CoV-2 immune response.

The clinical course and outcomes of immunocompromised patients, such as transplant recipients, with COVID-19 remain unclear. It has been postulated that a substantial portion of the disease burden seems to be mediated by the host immune activation to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present a simultaneous heart-kidney transplant (SHKT) recipient who was hospitalized for the management of respiratory failure from volume overload complicated by failure to thrive, multiple opportunistic infections, and open non-healing wounds in the setting of worsening

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of p … al (CI) 1.99 to 41.12; P = 0.004). There was no significant difference between treatment groups for cardiotoxicity and renal toxicity grade 3 or 4. None of the studies evaluated quality of life. The quality of evidence for the different outcomes was low. We found no eligible studies for possible otoprotective medical interventions other than amifostine and other …

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin and/or oxaliplatin, is used to treat a variety of paediatric malignanci … I) 1.99 to 41.12; P = 0.004). No significant difference was identified between treatment groups for cardiotoxicity and renal toxicity grade 3 or 4. None of the studies evaluated quality of life. No eligible studies were found for possible otoprotective medical interventions other than amifostine and other types of malignancies. AUTHORS' CONCLUSIONS: At the mome …

[Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].

PURPOSE: Chemotherapy and concurrent irradiation, intended to cure, are presently standard treatments for non metastatic, unresectable oesop … lays of more than one week, due to toxicity, occurred in 23.5%. Moreover, we observed 20.5% of mild cardiotoxicity and 6% of mild nephrotoxicity. No symptomatic lung fibrosis was observed. No death could be related to toxicity. Overall 2 year survival was 13%, with a median value of 10 months. Survival analysis, according to stage, showed 2 year values of 24% in …

Taxanes for adjuvant treatment of early breast cancer.

BACKGROUND: Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breast cancer. Taxanes are highly a … te-certainty evidence; 22 studies; 31,033 women). Taxanes probably cause little or no difference in cardiotoxicity compared to regimens without a taxane (OR 0.87, 95% CI 0.56 to 1.33; moderate-certainty evidence; 23 studies; 32,894 women). Seven studies reported low-quality evidence for QoL; overall, taxanes may make little or no difference in QoL compared to ch …

Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital.

BackgroundCardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial disparities in heart failure patients, minimal data is present for the cardio-oncology population.MethodsWe queried the echocardiogram database at a safety net hospital, defined by a high proportion of patients with Medicaid or no insurance, for patients who received HER2 receptor antagonists and/or anthracyclines from January 2016 to December 2018. Patient demographics, clinica…

The emerging role of echocardiography-based techniques in cardio-onco-hematology.

In decades, the overall survival rate for cancer patients has improved significantly with continuous advances in cancer treatment technologies. However, cancer therapeutics-related cardiac dysfunction (CTRCD) has been one of the most worrying side effects, particularly in patients with hematological malignancies (HM), affecting the quality of life for cancer survivors. Early detection and prompt treatment are of vital importance. Echocardiography-based techniques can even identify subclinical myocardial damages, which is crucial for preventing irreversible myocardial damage. Conventional trans

Совпадение в полном тексте источника
… HM and CVDs share many of the same risk factors and patients with HM who preexist CVDs are at increased risk for cardiotoxicity when exposed cardiotoxicity chemotherapeutics ( 20 , 21 ). … Furthermore, a greater cardiotoxic treatment burden was associated with larger RV functional impairment. …

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of p … with amifostine (risk ratio (RR) 9.04, 95% confidence interval (CI) 1.99 to 41.12). The effects on cardiotoxicity and renal toxicity grade 3 or 4 were uncertain (low-certainty evidence). None of the studies evaluated quality of life.In the recent update, we also identified one RCT including 109 children with localized hepatoblastoma evaluating the use of sodium …

Cardiovascular risk in cancer patients: initial experience from a cardio-oncology clinic in Mexico.

OBJECTIVE: To describe the cardiovascular risk from Mexican patients scheduled to initiate cancer treatment and to compare the risk between oncological and hematological malignancies. METHODS: We enrolled patients referred for echocardiography before initiating cancer therapies. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) was evaluated. To estimate the risk for developing cancer therapy-related cardiovascular toxicity (CTR-CVT) we used the Heart Failure Association-International Cardio-Oncology Society risk score (HFA-ICOS). RESULTS: 106 patients were studi

Совпадение в полном тексте источника
… These disparities could be partially explained by different cancer treatment regimens, demographics, patient-related CV risk factors, as well as previous use of cardiotoxic agents 14 . … HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry. Eur Heart J. 2022;43:ehac544.2591. 30. Rashed ER, Margulies KB. New cardiotoxicity risk assessment guidelines searching for validation. JACC CardioOncol. 2023;5:638–40. doi: 10.1016/j.jaccao.2023.06.006. 31. …

Evaluation of Subclinical Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Hematopoietic Stem Cell Transplantation: An Echocardiography Study.

Background: Hematopoietic stem cell transplantation (HSCT) is a potentially curative procedure that is used in various hematological malignancies. However, among an increasing number of HSCT, the amount of cancer therapy-related cardiac dysfunction (CTRCD) is increasing as well. This study aimed to determine the prevalence of subclinical CTRCD in HSCT patients 12 months after HSCT and to assess the impact of clinical factors on the development of CTRCD. Material and Methods: We included 55 patients who underwent autologous or allogeneic HSCT. The patients were assessed using an echocardiograph

Совпадение в полном тексте источника
… Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment. Curr. Treat. Options Cardio Med. 2014;16:315. doi: 10.1007/s11936-014-0315-4. 28. Henriksen P.A. Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. … Anthracycline-Induced Cardiotoxicity—Are We About to Clear This Hurdle? Eur. J. Cancer. 2023;185:94–104. doi: 10.1016/j.ejca.2023.02.019. 31. Chaulin A.M. The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin. Life. 2023;13:2148. doi: 10.3390/life13112148. 32. …

Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.

This review summarizes the current literature on the adverse cardiac effects of CAR T-cell therapy. Case reports and series suggest that major adverse cardiovascular events are not uncommon after CAR T-cell therapy; however, limited data exist regarding incidence, pathophysiology, and prevention strategies related to CAR T-associated cardiovascular events. As cellular therapy advances and the indications for its use continue to expand, it is essential to better understand its associated cardiovascular toxicities. Biomarkers, cardiac imaging, longitudinal data from larger populations, and trans

Совпадение в полном тексте источника
… Future Research Directions of CAR T-Cell Therapy A key research area in CAR T-cell treatment cardiotoxicity is to understand which clinical variables are associated with post-treatment cardiotoxicity. … Cardiac magnetic resonance imaging (MRI) has also yet to be studied in the context of CAR T-cell cardiotoxicity. …

Mechanisms of ferroptotic and non-ferroptotic organ toxicity of chemotherapy: protective and therapeutic effects of ginger, 6-gingerol and zingerone in preclinical studies.

Chemotherapy (CT) is one of the flagship options for the treatment of cancers worldwide. It involves the use of cytotoxic anticancer agents to kill or inhibit the proliferation of cancer cells. However, despite its clinical efficacy, CT triggers side effect toxicities in several organs, which may impact cancer patient's quality of life and treatment outcomes. While the side effect toxicity is consistent with non-ferroptotic mechanisms involving oxidative stress, inflammation, mitochondrial impairment and other aberrant signalling leading to apoptosis and necroptosis, recent studies show that f

Совпадение в полном тексте источника
… | In vitro H9c2 cells | | He et al. 2023 Doxorubicin | Cardiotoxicity | Rat | | Ouyang et al. 2023 Doxorubicin | Cardiotoxicity | Mouse | | Tadokoro et al. 2020 Doxorubicin | Cardiotoxicity | Mouse | | Liu et al. 2020 Doxorubicin | Cardiotoxicity | Mouse and neonatal rat cardiomyocytes | | Ou et … DOX, a widely used chemotherapeutic agent, is known for its cardiotoxic effects, mediated primarily through oxidative stress. 6G’s antioxidative property can mitigate DOX-induced cardiotoxicity. …

[The history of the development and changes of quinolone antibacterial agents].

The quinolones, especially the new quinolones (the 6-fluoroquinolones), are the synthetic antibacterial agents to rival the Beta-lactam and … e reactions, such as the CNS reaction, the drug-drug interaction, phototoxicity, hepatotoxicity and cardiotoxicity such as the QTc interval prolongation of ECG, have been reported in the clinical evaluations or the post-marketing surveillance of several new quinolones. Moreover, the adverse reactions of arthropathy (the joint toxicity) predicated from studies in …